GBA1 Gene and Gaucher Disease: Mutations and Clinical Trials

The GBA1 gene sits on chromosome 1q22, and its full name is glucosylceramidase beta 1. Older reports may call it GBA. Orphanet links GBA1 to 6 rare conditions and lists variants in the gene as a cause of 5 of them. Trial Friend's Gaucher Disease page lists GBA1 among the genes behind the condition. As of September 29, 2026, 9 recruiting or soon-opening trials on ClinicalTrials.gov name GBA1 as a gene.

See the trialsSearch another gene

What the GBA1 gene does

GBA1 makes an enzyme that works inside lysosomes, the cell's recycling centers. It breaks down a fatty molecule called glucocerebroside into glucose and ceramide so the parts can be reused.

Summarized from the GBA1 page on MedlinePlus Genetics, U.S. National Library of Medicine, checked September 29, 2026.

GBA1 and Gaucher Disease

These condition pages list GBA1 among the genes behind the condition, checked against genetics references when each page was written.

Gaucher Disease

The condition usually appears only when both copies of the gene carry a disease-causing variant. One variant alone usually means a person is a carrier.

All types (1, 2, 3) are caused by biallelic GBA1 variants; enzyme assay plus GBA1 sequencing confirms the diagnosis.

GBA1 mutation clinical trials

These recruiting or soon-opening trials mention GBA1 as a gene in their title, summary, eligibility rules or keywords. Some want people with a variant in it, and others study it more broadly, which is why each trial's own words are shown. In cancer trials the gene change is usually one found in the tumor rather than one a person inherited.

9 trials, checked September 29, 2026. The list refreshes from ClinicalTrials.gov every few hours.

RecruitingNCT06814431
Study on the Incidence of Malignant Neoplasms in Patients With Parkinson's Disease and Heterozygous Mutation of the GBA Gene
Idiopathic Parkinson's Disease (PD)
Why it's listed: “…sms in Parkinson's disease (PD) patients carrying heterozygous pathogenic variants in the GBA1 gene. The study compares these patients to individuals with idiopathic PD and to the general p…”
RecruitingPhase 1NCT06732180
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
Parkinson Disease
Why it's listed: “For participants with known GBA1 mutations, presence of a GBA1 mutation that has been associated with an increased risk of PD”
RecruitingNCT05843552
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
Gaucher Disease
Why it's listed: “…ir characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the sec…”
RecruitingNCT06993142
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
Parkinson Disease · Prodromal Stage · Neurodegenerative Diseases
Why it's listed: “…me and intensity of physical activity in daily life in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation over a long period of time (24 months). Second, to explore the preliminary efficacy of ex…”
RecruitingEarly Phase 1NCT06272149
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
Type II Gaucher Disease
Why it's listed: “…Historical diagnosis of Gaucher disease confirmed by GCase enzyme activity test, and with GBA1 biallelic mutations.”
RecruitingPhase 1, Phase 2NCT06818838
A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
Gaucher Disease Type 1
Why it's listed: “Gaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficienc…”
Opening soonEarly Phase 1NCT07685444
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
Parkinson's Disease (PD)
Why it's listed: “…s of LY-N001 Injection in patients with moderate-to-advanced Parkinson's disease carrying GBA1 mutations. The study consists of a main study phase and a long-term follow-up phase.”
Opening soonPhase 1, Phase 2NCT07414290
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
Parkinson Disease (PD)
Why it's listed: “Documented GBA1-mutant Parkinson's disease, confirmed by medical history: meeting the International Parkinson an…”
Opening soonNCT07474779
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
Parkinson's Disease (PD) · GBA1 Parkinson Disease · REM Sleep Behavior Disorder (iRBD)
Why it's listed: “…ross the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1 mutations. This interventional, monocentric, cross sectional study includes patients with PD, indiv…”

All conditions linked to GBA1 gene mutations

Orphanet records how each gene relates to each condition. Orphanet links GBA1 to 6 rare conditions and lists variants in the gene as a cause of 5 of them.

  • Causes it. Disease-causing variants in this gene are a direct cause of the condition.
  • Raises risk. Some variants raise the chance of the condition without guaranteeing it.
Fetal Gaucher diseaseCauses itTrial Friend pageOrphanet
Gaucher disease type 1Causes itTrial Friend pageOrphanet
Gaucher disease type 2Causes itTrial Friend pageOrphanet
Gaucher disease type 3Causes itTrial Friend pageOrphanet
Gaucher disease-ophthalmoplegia-cardiovascular calcification syndromeCauses itTrial Friend pageOrphanet
Hereditary late-onset Parkinson diseaseRaises riskOrphanet

GBA1 genetic test results and what a variant can mean

Labs sort each variant they find into 5 groups, from pathogenic and likely pathogenic through uncertain significance to likely benign and benign. Only the first 2 are usually treated as the cause of a condition. A variant of uncertain significance, or VUS, is one without enough evidence either way yet, and labs can reclassify it as research builds.

A genetic counselor or your doctor can explain what a specific result means for you and your family. Our genetic testing guide covers the terms, and MedlinePlus Genetics from the National Library of Medicine has a plain-language page on GBA1.

GBA1 gene questions

What does the GBA1 gene do?

GBA1 makes an enzyme that works inside lysosomes, the cell's recycling centers. It breaks down a fatty molecule called glucocerebroside into glucose and ceramide so the parts can be reused. This summary follows MedlinePlus Genetics from the U.S. National Library of Medicine.

Are there clinical trials for people with GBA1 gene variants?

As of September 29, 2026, 9 recruiting or soon-opening trials on ClinicalTrials.gov name GBA1 as a gene. Each one is listed on this page with the words from the trial that mention the gene. ClinicalTrials.gov also lists 31 open trials for Gaucher Disease, and Match Me on Trial Friend can check those against age, sex, location and treatment history.

What conditions are linked to the GBA1 gene?

Orphanet links GBA1 to 6 rare conditions and lists variants in the gene as a cause of 5 of them. They include Fetal Gaucher disease, Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome and Hereditary late-onset Parkinson disease. Orphanet is the European rare disease database run by INSERM in Paris.

How is Gaucher Disease inherited?

The inheritance pattern is autosomal recessive. The condition usually appears only when both copies of the gene carry a disease-causing variant. One variant alone usually means a person is a carrier. All types (1, 2, 3) are caused by biallelic GBA1 variants; enzyme assay plus GBA1 sequencing confirms the diagnosis.

What does a GBA1 variant of uncertain significance mean?

A variant of uncertain significance, or VUS, is a change in the gene that labs don't yet have enough evidence to call disease-causing or harmless. It is not used on its own to diagnose a condition, and labs can reclassify it as research builds. A genetic counselor can explain what a specific result means for you and your family.

Sources

  • Gene and condition links from Orphadata (Orphanet, INSERM US14), used under CC BY 4.0, read September 29, 2026.
  • Trials from ClinicalTrials.gov, read September 29, 2026.
  • GBA1 gene, MedlinePlus Genetics, U.S. National Library of Medicine.
  • Inheritance and gene notes from the Trial Friend condition pages above, each checked against genetics references.

Other gene pages

The gene search covers every gene Orphanet links to a rare disease.